NDAORALTABLET, EXTENDED RELEASE
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
DYANAVEL XR 5 (amphetamine) by Teva is non-catecholamine sympathomimetic amines with cns stimulant activity. Approved for attention-deficit/hyperactivity disorder. First approved in 2021.
Drug data last refreshed 20h ago
Mechanism of Action
non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
Pharmacologic Class:
Central Nervous System Stimulant
Indications (1)
Clinical Trials (20)
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
Started Feb 2026
40 enrolled
Methamphetamine IntoxicationMethamphetamine DisordersMethamphetamine Abuse
Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD)
Started Feb 2026
35 enrolled
Methamphetamine Abuse
Methamphetamine Use Disorder Support in Heart Failure Pilot Study
Started Nov 2025
50 enrolled
Heart FailureMethamphetamine Use Disorder
Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder
Started Sep 2024
20 enrolled
Methamphetamine Use Disorder
Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement
Started Aug 2024
200 enrolled
Methamphetamine UseHeart Failure
Worked on DYANAVEL XR 5 at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.